Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series

Trastuzumab-based regimes improved clinical outcome in women with overexpressing HER2 metastatic breast cancer, mainly due to the availability of different combination therapies, clinically active and well tolerated. In this study we retrospectively evaluated clinical activity and toxicity of trastu...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lauro, Vincenzo, Torrisi, Elena, Bidoli, Ettore, Quitadamo, Daniela, Cecco, Sara, Veronesi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321447/
https://www.ncbi.nlm.nih.gov/pubmed/22536237
http://dx.doi.org/10.1155/2012/198412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321447/
https://www.ncbi.nlm.nih.gov/pubmed/22536237
http://dx.doi.org/10.1155/2012/198412

Ejemplares similares